Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

PURPOSE: XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models. Early observations of clinical benefit in a phase I study of cabozantinib, which includ...

詳細記述

保存先:
書誌詳細
主要な著者: Kurzrock, Razelle, Sherman, Steven I., Ball, Douglas W., Forastiere, Arlene A., Cohen, Roger B., Mehra, Ranee, Pfister, David G., Cohen, Ezra E.W., Janisch, Linda, Nauling, Forlisa, Hong, David S., Ng, Chaan S., Ye, Lei, Gagel, Robert F., Frye, John, Müller, Thomas, Ratain, Mark J., Salgia, Ravi
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2011
主題:
Original Reports
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3646303/
https://ncbi.nlm.nih.gov/pubmed/21606412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.32.4145
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料